In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy
| Image |  |
|---|---|
| Description | scientific article published on 3 May 2022 |
| Author/s | |
| Publication date | May 3, 2022 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |